These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25103842)

  • 1. [Gastroenteropancreatic neuroendocrine tumors : targeted diagnostics and therapy].
    Holzer K
    Chirurg; 2014 Aug; 85(8):731-44. PubMed ID: 25103842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis.
    Laffi A; Spada F; Bagnardi V; Frassoni S; Pisa E; Rubino M; Barberis M; Fazio N
    J Endocrinol Invest; 2022 Feb; 45(2):317-325. PubMed ID: 34282554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
    Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
    Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
    Mosquera C; Koutlas NJ; Fitzgerald TL
    Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chinese expert consensus on gastroenteropancreatic neuroendocrine neoplasms (2022 edition)].
    Expert Committee on Neuroendocrine Neoplasms, Chinese Society of Clinical Oncology
    Zhonghua Zhong Liu Za Zhi; 2022 Dec; 44(12):1305-1329. PubMed ID: 36575783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial impact of a systematic multidisciplinary approach on the management of patients with gastroenteropancreatic neuroendocrine tumor.
    Tamagno G; Sheahan K; Skehan SJ; Geoghegan JG; Fennelly D; Collins CD; Maguire D; Traynor O; Brophy DP; Cantwell C; Swan N; McGowan L; O'Toole D; O'Shea D
    Endocrine; 2013 Oct; 44(2):504-9. PubMed ID: 23471696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
    Baeg K; Harris C; Naparst MS; Ahn E; Thapi S; Martin J; Rustgi S; Mhango G; Wisnivesky J; Kim MK
    BMC Cancer; 2021 Feb; 21(1):146. PubMed ID: 33563241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.
    Kaemmerer D; Peter L; Lupp A; Schulz S; Sänger J; Prasad V; Kulkarni H; Haugvik SP; Hommann M; Baum RP
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1659-68. PubMed ID: 21626438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors.
    Du S; Ni J; Weng L; Ma F; Li S; Wang W; Sang X; Lu X; Zhong S; Mao Y
    Medicine (Baltimore); 2015 Aug; 94(34):e1429. PubMed ID: 26313798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
    Perez K; Chan J
    Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    de Herder WW
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):689-90. PubMed ID: 23582912
    [No Abstract]   [Full Text] [Related]  

  • 14. Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.
    Coriat R; Walter T; Terris B; Couvelard A; Ruszniewski P
    Oncologist; 2016 Oct; 21(10):1191-1199. PubMed ID: 27401895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation.
    Niederle MB; Niederle B
    Oncologist; 2011; 16(5):602-13. PubMed ID: 21467149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia.
    Ptasnuka M; Ozolins A; Narbuts Z; Truskovs A; Sperga M; Plaudis H
    World J Surg; 2020 Feb; 44(2):585-593. PubMed ID: 31605174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastroenteropancreatic Neuroendocrine Tumors.
    Fernandes CJ; Leung G; Eads JR; Katona BW
    Gastroenterol Clin North Am; 2022 Sep; 51(3):625-647. PubMed ID: 36153114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The diagnosis and treatment of G3 neuroendocrine tumors according to the new NCCN guideline].
    Liang Y; Yu XJ; Chen J
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(14):982-987. PubMed ID: 35399015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highlights in GEP-NETs From the 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease: Commentary.
    Iyer R; Hatoum H
    Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):17-9. PubMed ID: 27168109
    [No Abstract]   [Full Text] [Related]  

  • 20. Peptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population: A two-year experience in a nonuniversity setting.
    Mejia A; Vivian E; Nwogu C; Shah J; Longoria R; Vo A; Shahin I; Verma J; Bageac A
    Medicine (Baltimore); 2022 Mar; 101(9):e28970. PubMed ID: 35244064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.